Simtra BioPharma Solutions, a leading player in the biopharmaceutical industry, is making significant strides in expanding its manufacturing capabilities both in the United States and globally. The company recently unveiled a state-of-the-art production facility in Halle, Germany, marking a pivotal moment in its commitment to advancing the development and delivery of innovative therapies.
Franco Negron, the CEO of Simtra, emphasized the importance of this expansion in accelerating the production of vital treatments, particularly targeted cancer therapies, and ensuring timely access for patients in need. This strategic move underscores Simtra’s dedication to meeting the evolving demands of the market and enhancing its expertise in large-scale vial filling and cutting-edge technologies like prefilled syringes.
Read more from pharmexec.com